Top Story

ICER council votes on effectiveness, value of NSCLC therapies

ICER council votes on effectiveness, value of NSCLC therapies
October 21, 2016

The Midwest Comparative Effectiveness Public Advisory Council program of the Institute for Clinical and Economic Review yesterday generally voted in favor of the net-health benefit and long-term value of tyrosine kinase inhibitors for the treatment of non–small cell lung cancer.

Although Midwest Comparative Effectiveness Public Advisory Council (CEPAC) generally voted that individual PD-1 inhibitors provide a greater net-health benefit than docetaxel in their approved settings, the council tended to vote that these agents had low to intermediate long-term monetary value.

In the Journals Plus

Health insurance expansion may increase access to colorectal cancer care

October 21, 2016
A 2006 Massachusetts health care reform that served as a model for the Affordable Care Act increased rates of resection and decreased probability of emergent resection…

ACR asks for FDA guidelines on biosimilar substitution

October 21, 2016
During a public meeting on the reauthorization of the Biosimilar User Free Act, Angus Worthing, MD, FACR, FACP, incoming chair of the American College of…

Keytruda improves OS in advanced bladder cancer, study closes early

October 21, 2016
A phase 3 study comparing pembrolizumab to chemotherapy for patients with advanced, previously treated urothelial cancer met its primary OS endpoint and has closed…

Xgeva demonstrates noninferiority in delaying time to bone complications in multiple myeloma

October 21, 2016
Denosumab demonstrated noninferiority compared with zoledronic acid in delaying time to first on-study skeletal-related event in patients with multiple myeloma…
More News Headlines »

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Meeting News Coverage

VIDEO: Noninvasive follicular thyroid neoplasms cause little risk for patients

September 23, 2016
More »
CME Video

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-Line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Current Issues
View the Current Issue
HemOnc Today